TolebrutinibocrelizumabPPMSsecondary progressive MSprimary progressive MSPERSEUSNCT04458051
…Background Tolebrutinib, an oral, brain-penetrant, bioactive Bruton’s tyrosine kinase i…
24articles mentioning drugs
67drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Ocrelizumab ×
Ocrelizumab
This drug is selected. Its supporting articles are shown below.
Articles mentioning Ocrelizumab
24 articles · page 2 of 2ocrelizumabofatumumabmultiple sclerosisMSB cell therapy
…re assessed every 6–12 months.Results 195 patients treated with ocrelizumab or ofatumumab, with a mean age of 49.1 (±12.4) years, were foll…
ocrelizumabJNNPmultiple sclerosisanti-CD20 therapies
…table patients with multiple sclerosis (MS), discontinuation of ocrelizumab after about 30 months was not associated with a statistically s…
ocrelizumabnatalizumabofatumumabrituximabmAb-BFDMTmultiple sclerosisneuromyelitis optica spectrum disorderGerman MS and Pregnancy Registrydisease-modifying therapy
…nfants, most were breastfed on natalizumab (n=125), followed by ocrelizumab (n=34), rituximab (n=11) and ofatumumab (n=10); three had multi…
ocrelizumabimmunoglobulinsplasma exchangemultiple sclerosisprimary CNS vasculitisdemyelinating central nervous system (CNS) disease
…gressive multiple sclerosis was established. Immunotherapy with ocrelizumab resulted in clinical stabilisation. This case highlights the di…
ocrelizumabbreast cancerprimary progressive multiple sclerosisFDAUS Food and Drug AdministrationPPMS
…tration (FDA) is reviewing a petition to revoke the approval of ocrelizumab for the treatment of primary progressive multiple sclerosis (PP…
ofatumumabocrelizumabteriflunomidenatalizumabcladribineglatiramer acetatedimethyl fumaratemultiple sclerosistertiary hospital
…n. It is noticed that two patients switched from ocrelizumab to ofatumumab: one due to infusion-related adverse effects and another for lo…
teriflunomidefingolimodinterferon betaglatiramer acetateocrelizumabrituximabdimethyl fumarateRIFUND-MSDMF
…a vs glatiramer acetate), RIFUND-MS (rituximab vs DMF), TENERE (teriflunomide vs interferon beta) and TRANSFORMS (fingolimod vs interferon be…
AlemtuzumabnatalizumabocrelizumabRRMSCardiffrelapsing-remitting multiple sclerosisCambridge
…Introduction Alemtuzumab is a potent disease-modifying therapy (DMT) for relapsing-remit…
ocrelizumabOCRPwRMSPw) relapsing and primary progressive multiple sclerosis
…( NCT03972306) and II (NCT05232825) show that subcutaneous (SC) ocrelizumab (OCR) 920 mg has a similar benefit-risk profile to intravenous …
natalizumabocrelizumabrituximabmultiple sclerosisMShigh-efficacy therapymonoclonal antibodies
… were identified in three MS registries. Patients who commenced natalizumab, ocrelizumab, or rituximab between ages 12–17 into the early tr…
rituximabobinutuzumab
…ies rendering it capable of superior B-cell killing compared to rituximab.5 The NOBILITY trial, a phase 2 clinical trial in patients with…